

Special Issue

Application of Peptide-Drug-Conjugates in the Treatment of Cancer and Microbial Infections

Message from the Guest Editors

According to the World Health Organization (WHO), antimicrobial resistance (AMR) is one of the top ten global public health threats that humanity is facing, while in 2019 cancer disease became the leading cause of death in the industrialized countries. PDC therapeutics combine one or more small drug molecules conjugated, most often, to a cell-penetrating peptide (CPP) either directly or through a biodegradable linker. This integration of two bioactive elements into a single entity often provides novel functionalities and improved bioavailability to treat conditions where conventional drugs are ineffective. With this Special Issue we would like to provide readers with the latest developments and innovations in the design and synthesis of peptide–drug conjugates that are used to target various infectious diseases and cancers. Therefore, we are interested in articles related to new chemical and conjugation strategies for developing efficient antimicrobial and anticancer PDCs using in vitro models, in vivo trials and with possible application in the pharmaceutical industry.

Guest Editors

Dr. Toni Todorovski
Prof. Dr. Daniela Kalafatovic
Prof. Dr. Michael A. Firer

Deadline for manuscript submissions

closed (20 May 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/110904

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.7 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the second half of 2025).